NZ629621A - Alpha-1-microglobulin for use in the treatment of mitochondria-related diseases - Google Patents

Alpha-1-microglobulin for use in the treatment of mitochondria-related diseases

Info

Publication number
NZ629621A
NZ629621A NZ629621A NZ62962113A NZ629621A NZ 629621 A NZ629621 A NZ 629621A NZ 629621 A NZ629621 A NZ 629621A NZ 62962113 A NZ62962113 A NZ 62962113A NZ 629621 A NZ629621 A NZ 629621A
Authority
NZ
New Zealand
Prior art keywords
microglobulin
mitochondria
alpha
treatment
related diseases
Prior art date
Application number
NZ629621A
Other languages
English (en)
Inventor
Bo Akerström
Magnus Gram
Lena Rosenlöf
Original Assignee
A1M Pharma Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by A1M Pharma Ab filed Critical A1M Pharma Ab
Publication of NZ629621A publication Critical patent/NZ629621A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1722Plasma globulins, lactoglobulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
NZ629621A 2012-09-05 2013-09-04 Alpha-1-microglobulin for use in the treatment of mitochondria-related diseases NZ629621A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201270538 2012-09-05
DKPA201270557 2012-09-12
PCT/EP2013/068270 WO2014037390A1 (en) 2012-09-05 2013-09-04 Alpha-1-microglobulin for use in the treatment of mitochondria-related diseases

Publications (1)

Publication Number Publication Date
NZ629621A true NZ629621A (en) 2015-09-25

Family

ID=49162118

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ629621A NZ629621A (en) 2012-09-05 2013-09-04 Alpha-1-microglobulin for use in the treatment of mitochondria-related diseases

Country Status (21)

Country Link
US (1) US10226507B2 (forum.php)
EP (1) EP2900254B1 (forum.php)
JP (2) JP2015533790A (forum.php)
KR (1) KR20150047510A (forum.php)
CN (1) CN104661673A (forum.php)
AU (1) AU2013311714C1 (forum.php)
BR (1) BR112015003957A2 (forum.php)
CA (1) CA2881321A1 (forum.php)
DK (1) DK2900254T3 (forum.php)
EA (1) EA028963B1 (forum.php)
ES (1) ES2599034T3 (forum.php)
HR (1) HRP20161364T1 (forum.php)
HU (1) HUE030559T2 (forum.php)
IN (1) IN2015DN00515A (forum.php)
MX (1) MX357656B (forum.php)
NZ (1) NZ629621A (forum.php)
PL (1) PL2900254T3 (forum.php)
PT (1) PT2900254T (forum.php)
SG (1) SG11201500669SA (forum.php)
WO (1) WO2014037390A1 (forum.php)
ZA (1) ZA201500547B (forum.php)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016204360A (ja) * 2015-02-25 2016-12-08 エー1エム ファーマ エービーA1M Pharma AB 放射性核種療法における腎臓の保護に用いるためのアルファ−1−ミクログロブリン
CA3014850A1 (en) * 2016-02-25 2017-08-31 A1M Pharma Ab Alpha-1-microglobulin for use in the protection of kidneys in connection with use of contrast media
CN108779157B (zh) * 2016-03-18 2022-12-30 卫士医疗国际公司 新α-1-微球蛋白衍生蛋白及其应用
GB2566516A (en) 2017-09-15 2019-03-20 Univ Oxford Innovation Ltd Electrochemical recognition and quantification of cytochrome c oxidase expression in bacteria
CN109867717A (zh) * 2019-04-01 2019-06-11 山西瑞亚力生物技术有限公司 一种血浆中α1微球蛋白的提取方法
CN110452980B (zh) * 2019-09-23 2023-07-28 武汉儿童医院 一种线粒体脑肌病诊断试剂盒及应用
US20220362293A1 (en) * 2019-09-25 2022-11-17 Cytegen Corp. Treatment of Mitochondrial Deficits and Age-Related Diseases Using Blood Products
CN115575646B (zh) * 2022-11-21 2023-04-28 四川大学华西医院 一种代谢标志物组在制备预测癫痫发作的试剂盒中的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1882331A (zh) * 2003-11-26 2006-12-20 塞诺菲-安万特德国有限公司 作为心血管风险升高指示剂的肾小管性蛋白尿
ES2599003T3 (es) * 2007-02-12 2017-01-31 A1M Pharma Ab Diagnóstico y tratamiento de preeclampsia
HRP20160024T1 (hr) * 2008-02-04 2016-02-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Metode i sastavi za lijeäśenje mitohondrijskih poremeä†aja
PT2638915T (pt) * 2008-07-18 2017-01-10 A1M Pharma Ab Utilização médica da alfa 1-microglobulina antioxidante e eliminadora de radicais

Also Published As

Publication number Publication date
US20150258171A1 (en) 2015-09-17
CN104661673A (zh) 2015-05-27
BR112015003957A2 (pt) 2017-08-08
CA2881321A1 (en) 2014-03-13
PL2900254T3 (pl) 2017-02-28
MX2015002604A (es) 2015-06-10
SG11201500669SA (en) 2015-02-27
EP2900254B1 (en) 2016-08-03
DK2900254T3 (en) 2016-08-29
EA201590503A1 (ru) 2015-06-30
AU2013311714A1 (en) 2015-03-12
EP2900254A1 (en) 2015-08-05
HUE030559T2 (en) 2017-05-29
HK1210585A1 (en) 2016-04-29
IN2015DN00515A (forum.php) 2015-06-26
PT2900254T (pt) 2016-10-18
AU2013311714C1 (en) 2018-01-25
JP2018203756A (ja) 2018-12-27
AU2013311714B2 (en) 2017-10-12
ZA201500547B (en) 2017-09-27
JP2015533790A (ja) 2015-11-26
US10226507B2 (en) 2019-03-12
EA028963B1 (ru) 2018-01-31
ES2599034T3 (es) 2017-01-31
HRP20161364T1 (hr) 2016-12-16
KR20150047510A (ko) 2015-05-04
WO2014037390A1 (en) 2014-03-13
MX357656B (es) 2018-07-18

Similar Documents

Publication Publication Date Title
NZ629621A (en) Alpha-1-microglobulin for use in the treatment of mitochondria-related diseases
Mayama Calcium channels and their blockers in intraocular pressure and glaucoma
IL276016B (en) Ocular formulations for administration of drug to the back of the eye
BR112016029675A2 (pt) dispositivos dilatadores nasais
MX2016014634A (es) Compuestos para el tratamiento de enfermedades y trastornos oftalmicos.
AR088165A1 (es) Proteinas de funcion dual para tratar trastornos metabolicos
IL273531A (en) Ophthalmic preparations containing latanoprost for use in the treatment of eye diseases
MY171920A (en) Prevention and treatment of ocular conditions
HUE046963T2 (hu) Készítmények és kezelés szembetegségekhez és rendellenességekhez
CY1120642T1 (el) Φαρμακευτικη συνθεση της ιβουπροφαιμνης και της τραμαδολης για οφθαλμολογικη χρηση
CO2017000346A2 (es) Anticuerpos de unión a protofibrillas aβ
MX390084B (es) Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos.
ECSP11010956A (es) Compuestos enlazados con azufre para el tratamiento de enfermedades y trastornos oftalmicos
MX2025001445A (es) Anticuerpos monoclonales anti-trkb y metodos de uso
HK1231376A1 (zh) 局部制剂及其应用
WO2015048188A3 (en) Modified fibroblast growth factors for the treatment of ocular disorders
UY33153A (es) Formulación tópica oftálmica de péptidos
MA56220A (fr) Formulations oculaires permettant l'administration de médicament et la protection du segment antérieur de l'oeil
IT1398378B1 (it) Citicolina per il trattamento del glaucoma e dell'ipertensione oculare.
ZA202003944B (en) Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye
BR102013000808A8 (pt) levantador para produto de colheita
CA2909622C (en) Quinone based nitric oxide donating compounds for ophthalmic use
BR112017014379A2 (pt) composição para o tratamento de infecções causadas pelo acaro demodex spp
BR112017021374A2 (pt) ácido pirrolidona carboxílico (pca) para uso oftálmico
AR081769A1 (es) Derivados indazolicos e intermediarios para su produccion, utiles como agentes profilacticos o terapeuticos para enfermedades degenerativas coriorretinales

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 SEP 2018 BY CPA GLOBAL(PATRAFEE)

Effective date: 20170825

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 SEP 2019 BY CPA GLOBAL(PATRAFEE) AB

Effective date: 20180808

LAPS Patent lapsed